Vaccine Safety and Pharmacovigilance Strategies (Beijing, China)

Documents

l4_1_practical_considerations.pdf

l4_2_quality_management.pdf

l4_3_dsurs.pdf

l3_1_active_pharmacovigilance.pdf

l3_2_signal_detection.pdf

l3_3_pm_aggregate_reporting_psur_.pdf

l2_1_eu_and_us_specific_requirements.pdf

l2_2_principles_clinical_safety.pdf

l2_3_post_marketing_pv_part_1.pdf

l4_4monitoring_literature.pdf

l1_4_basic_elements_pv_system.pdf

l1_1_importance_of_pv.pdf

l1_2_legal_framework.pdf

l1_3_specifics_of_vaccine_pv.pdf

beijing_workshop_agenda_final_1.pdf

path_introduction20170429.pdf

2017_rodewald_-_beijing_dcvmn_-_it_takes_a_program_to_vaccinate_safely_and_effectively.pdf

munters_humidity_control_vs_microorganisms_april_2017.pdf

e1_1_illustrate_importance_of_pv.pdf

e1_2_practical_exercies_basic_pv.pdf

exercise_2.2_instructions.pdf

cioms_blank_form.pdf

set_of_individual_safety_report.pdf

---

---